

Press Release

Martin Kunze
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2115
F +49 6172 608-2294
martin.kunze@fresenius.com
www.fresenius.com

December 23, 2019

Fresenius Helios acquires leading private hospital in Colombia

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company's presence in Colombia's attractive private hospital market.

CMI is located in a central district of Cali, the biggest city in southwestern Colombia with a population of 2.4 million. As one of the most prestigious private hospitals in Latin America, repeatedly recognized for its medical quality as well as its state-of-the-art infrastructure and medical technology, CMI offers a comprehensive range of medical specialties and services. The hospital has about 350 beds, 17 operating rooms and 250 consultation rooms, and generated sales of about €130 million in 2018. The total consideration amounts to approximately €300 million.

The purchase of CMI is another important step in strengthening Quirónsalud's presence in Colombia's growing and consolidating healthcare services market. With this acquisition, Quirónsalud becomes one of the leading private hospital operators in the country. The transaction is expected to close in the first quarter of 2020, pending anti-trust clearance. Fresenius expects CMI to be accretive to Group net income¹ in fiscal year 2020.

#

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2018, Group sales were €33.5 billion. On September 30, 2019, the Fresenius Group had 292,635 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Social Media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick